Leukemia
Conditions
Brief summary
To characterize the metabolism of glucose by the leukemic cells in patients with leukemia before and after initial chemotherapy. To compare the metabolism of glucose by leukocytes in healthy volunteers and leukemic cells in leukemic patients.
Detailed description
To characterize glycolytic metabolism in patients as demonstrated in leukemic cells and serum metabolite analysis after C13-glucose administration at strategic time points of treatment. To detect and measure 13C-labeled metabolic markers which may be present in the serum and urine of leukemic patients. To characterize glycolytic metabolism in patients as demonstrated in leukemic cells and serum metabolite analysis after C13-glucose administration at strategic time points of treatment. To detect and measure 13C-labeled metabolic markers which may be present in the serum and urine of leukemic patients.
Interventions
None listed
Sponsors
James Graham Brown Cancer Center
University of Louisville
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
for Leukemia Subjects: * Each of the criteria in the following section must be met in order for a patient to be eligible for enrollment. * Only patients with clinically diagnosed or histologically diagnosed leukemia will be eligible to participate in this non-therapeutic study. * All patients must have measurable quantities of leukemic blasts on peripheral blood detected with a CBC. * No history of diabetes for the experimental group or the control group. * Patients with known hepatitis C or HIV (AIDS) are excluded. * Patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines. Inclusion Criteria forHealthy Subjects: * Subjects must have no known prior history of cancer or malignant blood disorders. -Where possible, follow up will be carried out to verify that no cancer has developed since the blood collection. This will be done by a phone call performed one month from sample to ask if new medical conditions have arisen. * Subjects must have WBC, RBC, and platelet counts within normal range on CBC. * Subjects with known hepatitis C or HIV (AIDS) are excluded. * No history of Diabetes * At least 30 years of age * Preferably be fasting for 12 hours (minimum 8 hours) prior to enrollment * Patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.
Exclusion criteria
* None listed in protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic characteristics of leukemic cells from blood and urine samples using nuclear magnetic resonance spectroscopy (NMR) | Baseline up to 6 months post treatment | Blood and urine samples will be taken before and after chemotherapy treatment for up to 6 months post treatment and analyzed for metabolic substances using nuclear magnetic resonance (NMR) spectroscopy with intergraded hyphenated mass spectrometry. |
Countries
United States
Outcome results
None listed